MRK · Full Picture

Merck & Co., Inc. — the full picture

Earnings window · 2026-07-17 to 2026-08-09 · anchored on the 10-Q report

One earnings window, everything merged: the filing, the call, press releases and news digests, folded into ranked threads.

What to look at first

1. Guidance / Outlook · Guidance & outlookPriority 96
   -59.3% net_income; 3 sources (news, press_release, sec_filing); 5 forward row(s); quote_verified
   Merck raised its full-year 2026 sales outlook to between $66.3 billion and $67.3 billion.
2. Operating Expense Trends · Operating expenses (SG&A)Priority 86
   -31.0% operating_income; 2 sources (press_release, sec_filing); 2 forward row(s); structured_verified
   Full-year 2026 updated non-GAAP operating expenses are expected to be $42.0 billion to $42.7 billion, up from prior $36.0 billion to $36.8 billion; includes one-time R&D charges of $9.0 billion for acquisition of Cidara and $5.7 billion for acquisition of Terns
3. Acquisition / Partnership / Divestiture · M&A and divestituresPriority 85
   -34.3% operating_income (realized); 3 sources (news, press_release, sec_filing); quote_verified
   Completed acquisition of Terns for $6.8 billion and added MK-4208, an investigational oral allosteric BCR::ABL1 tyrosine kinase inhibitor recently granted BTD by FDA
4. Research and Development Expense · R&D investmentPriority 78
   -122.6% operating_income (realized); structured_verified
   Research and development expenses increased to $9,741 million in Q2 2026 and $22,333 million in the first six months of 2026, compared with $4,048 million and $7,669 million in Q2 and YTD 2025, primarily due to higher charges for business development activity.
5. Gross Margin Drivers · Gross marginPriority 77
   -0.8% margin; 2 sources (press_release, sec_filing); 1 forward row(s); quote_verified
   Full-year 2026 updated non-GAAP gross margin is approximately 81%, down from prior approximately 82%
6. Revenue Performance and Mix · Revenue growth & mixPriority 73
   +14.0% revenue (realized); 3 sources (news, press_release, sec_filing); quote_verified
   Total Worldwide Sales were $16.6 Billion in Q2 2026, 5% Growth; 4% Growth ex-FX
7. Competition and Pricing Pressure · Competition & market sharePriority 63
   2 sources (press_release, sec_filing); 1 forward row(s); quote_verified
   Dificid worldwide sales declined 77% and 69% in the second quarter and first six months of 2026, respectively, due to generic competition in the U.S.; Dificid lost market exclusivity in the U.S. in July 2025.
8. Income Tax Rate Changes · TaxPriority 56
   2 sources (press_release, sec_filing); 1 forward row(s); quote_verified
   Full-year 2026 updated non-GAAP effective income tax rate is expected to be 35.0% to 36.0% (prior 23.5% to 24.5%), including impact of non-tax deductible one-time charges for Cidara and Terns
9. Outstanding Indebtedness · Debt, leverage & refinancingPriority 56
   qualitative only
10. FX / Currency Headwinds · Currency / FXPriority 55
    +3.4% revenue; 1 forward row(s); quote_verified
    The company anticipates full-year 2026 sales to include a positive impact from foreign exchange of approximately 1% at mid-July 2026 exchange rates
11. Competition and Market Share · Competition & market sharePriority 53
    quote_verified
    Jennifer Taubert will retire on September 1, 2026 after a 21-year tenure.
12. Headcount / Restructuring · Restructuring & impairmentPriority 53
    +2.5% operating_income (realized); 2 sources (press_release, sec_filing); quote_verified
    Second-quarter restructuring costs were $151 million in Q2 2026 compared with $560 million in Q2 2025 (down 73%)

Threads by pillar

Revenue & Demand Priority 87 · 8 threads

• Revenue Performance and MixPriority 73 · News, Release, Filing
• Product Launch and TransitionPriority 46 · News, Release
• Product and Pipeline ProgressPriority 38 · News, Release
• Products and TechnologyPriority 31 · Filing
• Geographic Market CommentaryPriority 46 · News, Release, Filing
• Animal Health DemandPriority 37 · Filing
• Market Demand TrendsPriority 37 · Release
• Pricing and Market AccessPriority 41 · Filing

Costs & Margins Priority 95 · 5 threads

• Operating Expense TrendsPriority 86 · Release, Filing
• Research and Development ExpensePriority 78 · Filing
• Gross Margin DriversPriority 77 · Release, Filing
• Headcount / RestructuringPriority 53 · Release, Filing
• Supply Chain and InventoryPriority 28 · Filing

Capital & Balance Sheet Priority 75 · 5 threads

• Outstanding IndebtednessPriority 56 · Filing
• Liquidity and Debt PositionPriority 46 · Filing
• Income Tax Rate ChangesPriority 56 · Release, Filing
• Capital Return ProgramPriority 46 · Filing
• Quarterly Dividend DeclarationPriority 28 · News

Strategy & Portfolio Priority 85 · 1 thread

• Acquisition / Partnership / DivestiturePriority 85 · News, Release, Filing

Legal, Regulatory & Policy Priority 65 · 7 threads

• Regulatory Approval MilestonesPriority 38 · News, Release
• Regulatory RiskPriority 37 · Filing
• Regulatory Pipeline ProgressPriority 32 · Filing
• Vaccine Policy LitigationPriority 41 · Filing
• India Litigation JurisdictionPriority 30 · News
• Litigation and Legal RiskPriority 28 · News
• Trade Policy and TariffsPriority 40 · Filing

Guidance & Outlook Priority 96 · 1 thread

• Guidance / OutlookPriority 96 · News, Release, Filing

Macro & Market Conditions Priority 69 · 3 threads

• Competition and Pricing PressurePriority 63 · Release, Filing
• Competition and Market SharePriority 53 · News
• FX / Currency HeadwindsPriority 55 · Release

Unclassified Priority 68 · 5 threads

• German Health-Care ReformPriority 40 · Filing
• Lagevrio U.S. Market TransitionPriority 39 · Filing
• Clinical Pipeline DevelopmentsPriority 34 · Filing
• Single-Dose HPV Vaccine ResearchPriority 33 · Filing
• Manufacturing Network OptimizationPriority 31 · Filing

Expected impact by metric